Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ptc Therapeutics (PTCT)

Ptc Therapeutics (PTCT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,550,513
  • Shares Outstanding, K 58,431
  • Annual Sales, $ 264,730 K
  • Annual Income, $ -128,080 K
  • 60-Month Beta 1.79
  • Price/Sales 9.70
  • Price/Cash Flow N/A
  • Price/Book 5.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.39
  • Number of Estimates 2
  • High Estimate -0.28
  • Low Estimate -0.49
  • Prior Year -0.09
  • Growth Rate Est. (year over year) -333.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.13 +8.89%
on 05/29/19
44.13 -3.44%
on 06/20/19
+3.14 (+7.96%)
since 05/24/19
3-Month
34.51 +23.47%
on 04/18/19
44.13 -3.44%
on 06/20/19
+4.90 (+12.99%)
since 03/22/19
52-Week
27.53 +54.78%
on 01/28/19
48.99 -13.02%
on 10/01/18
+6.60 (+18.33%)
since 06/22/18

Most Recent Stories

More News
PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental New Drug Application (sNDA) for Emflaza® (deflazacort) to expand...

PTCT : 42.64 (-2.31%)
Ptc Therapeutics Shares Up 24.8% Since SmarTrend's Buy Recommendation (PTCT)

SmarTrend identified an Uptrend for Ptc Therapeutics (NASDAQ:PTCT) on February 22nd, 2019 at $32.16. In approximately 3 months, Ptc Therapeutics has returned 24.80% as of today's recent price of $40.13....

PTCT : 42.64 (-2.31%)
PTC Therapeutics Promotes Emily Hill to Chief Financial Officer

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Emily Hill to Chief Financial Officer. Ms. Hill joined PTC Therapeutics in November 2013 and was most recently Senior Vice President...

PTCT : 42.64 (-2.31%)
PTC Therapeutics to Participate at Upcoming Investor Conference

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Jefferies Healthcare Conference on Thursday, June 6th at 4:00 p.m. ET.

PTCT : 42.64 (-2.31%)
PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the three funding recipients from PRIORITY, an annual program to support outstanding clinical research by the rare genetic disorders community. This...

PTCT : 42.64 (-2.31%)
PTC Therapeutics and MRI Interventions Announce Strategic Investment

PTC Therapeutics, Inc. (NASDAQ: PTCT) and MRI Interventions, Inc. (OTCQB: MRIC) today announced a strategic equity investment, with PTC purchasing $4.0 million in shares of MRI common stock. PTC and MRI...

PTCT : 42.64 (-2.31%)
MRIC : 3.1500 (-1.25%)
Shares of PTCT Up 22.5% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Ptc Therapeutics (NASDAQ:PTCT) on February 22nd, 2019 at $32.16. In approximately 3 months, Ptc Therapeutics has returned 22.53% as of today's recent price of $39.40....

PTCT : 42.64 (-2.31%)
Biotech Stocks: Global Revenues for Ophthalmology Market Projected to Reach $26 Billion by 2022

As the baby boomer generation ages, there is an increased need no a demand by these aging patients to avert vision and blindness problems that come with aging. An industry report GBI Research stated that...

PTCT : 42.64 (-2.31%)
GHSI : 1.34 (-0.74%)
RMTI : 2.97 (-0.67%)
BSGM : 8.78 (-5.08%)
VRAY : 8.67 (-0.57%)
Shares of Ptc Therapeutics Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (PTCT , AMAG , PRTA , GBT , MRTX)

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

PTCT : 42.64 (-2.31%)
PRTA : 9.51 (-2.36%)
AMAG : 8.44 (-5.91%)
MRTX : 101.61 (+0.17%)
PTC Therapeutics to Participate at Upcoming Investor Conferences

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences:

PTCT : 42.64 (-2.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade PTCT with:

Business Summary

PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.

See More

Key Turning Points

2nd Resistance Point 44.50
1st Resistance Point 44.07
Last Price 42.64
1st Support Level 42.86
2nd Support Level 42.08

See More

52-Week High 48.99
Last Price 42.64
Fibonacci 61.8% 40.79
Fibonacci 50% 38.26
Fibonacci 38.2% 35.73
52-Week Low 27.53

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar